Evaluation of the Driving Performance and User Acceptance of a Predictive Eco-Driving Assistance System for Electric Vehicles

In this work, a predictive eco-driving assistance system (pEDAS) with the goal to assist drivers in improving their driving style and thereby reducing the energy consumption in battery electric vehicles while enhancing the driving safety and comfort is introduced and evaluated. pEDAS in this work is equipped with two model predictive controllers (MPCs), namely reference-tracking MPC and car-following MPC, that use the information from onboard sensors, signal phase and timing (SPaT) messages from traffic light infrastructure, and geographical information of the driving route to compute an energy-optimal driving speed. An optimal speed suggestion and informative advice are indicated to the driver using a visual feedback. pEDAS provides continuous feedback and encourages the drivers to perform energy-efficient car-following while tracking a preceding vehicle, travel at safe speeds at turns and curved roads, drive at energy-optimal speed determined using dynamic programming in freeway scenarios, and travel with a green-wave optimal speed to cross the signalized intersections at a green phase whenever possible. Furthermore, to evaluate the efficacy of the proposed pEDAS, user studies were conducted with 41 participants on a dynamic driving simulator. The objective analysis revealed that the drivers achieved mean energy savings up to 10%, reduced the speed limit violations, and avoided unnecessary stops at signalized intersections by using pEDAS. Finally, the user acceptance of the proposed pEDAS was evaluated using the Technology Acceptance Model (TAM) and Theory of Planned Behavior (TPB). The results showed an overall positive attitude of users and that the perceived usefulness and perceived behavioral control were found to be the significant factors in influencing the behavioral intention to use pEDAS.Comment: Submitted to Transportation Research Part C: Emerging Technologies Journa

Influence of the Chemical Composition of the Used Powder on the Fatigue Behavior of Additively Manufactured Materials

To exploit the whole potential of Additive Manufacturing (AM), a sound knowledge about the mechanical and especially cyclic properties of AM materials as well as their dependency on the process parameters is indispensable. In the presented work, the influence of chemical composition of the used powder on the fatigue behavior of Selectively Laser Melted (SLM) and Laser Deposition Welded (LDW) specimens made of austenitic stainless steel AISI 316L was investigated. Therefore, in each manufacturing process two variations of chemical composition of the used powder were utilized. For qualitative characterization of the materials cyclic deformation behavior, load increase tests (LITs) were performed and further used for the physically based lifetime calculation method (PhyBaLLIT), enabling an efficient determination of stress (S)–number of cycles to failure (Nf) curves (S–Nf), which show excellent correlation to additionally performed constant amplitude tests (CATs). Moreover, instrumented cyclic indentation tests (PhyBaLCHT) were utilized to characterize the materials’ defect tolerance in a comparably short time. All material variants exhibit a high influence of microstructural defects on the fatigue properties. Consequently, for the SLM process a higher fatigue lifetime at lower stress amplitudes could be observed for the batch with a higher defect tolerance, resulting from a more pronounced deformation induced austenite–α’-martensite transformation. In correspondence to that, the batch of LDW material with an increased defect tolerance exhibit a higher fatigue strength. However, the differences in defect tolerance between the LDW batches is only slightly influenced by phase transformation and seems to be mainly governed by differences in hardening potential of the austenitic microstructure. Furthermore, a significantly higher fatigue strength could be observed for SLM material in relation to LDW specimens, because of a refined microstructure and smaller microstructural defects of SLM specimens

Aktuelle Berichte und Forschungsprojekte

Internationale sprachwissenschaftliche Konferenz "Korpuslinguistik Deutsch-Tschechisch kontrastiv" in Sambachshof und Würzburg, 06.-08. Oktober 2009 (Iva Kratochvílová, Norbert Richard Wolf) "Tschechen und Deutsche im 20. und 21. Jahrhundert. Neue Sichtweisen auf alte Probleme." Deutsch-tschechisches Seminar in Sankelmark, 09.-11. Oktober 2009 (Jarmila Jehličková) Von der Grenze zum Dazwischen. Ein tschechisch-österreichisches Projekt zur Grenze und der Veränderung ihrer Wahrnehmung in Wien, 9.-11. November 2009 und Brünn 7.-10. Dezember 2009 (Michaela Kropik, Katharina Wessely) Bericht über den V. Germanisten-Kongress in Sevilla, 16.-18. Dezember 2009 (Fernando Magallanes) Bericht über die Linguistik-Tage in Freiburg im Breisgau, 02.-04. März 2010 (Martin Lachout) Sprachliches Wissen zwischen Lexikon und Grammatik. Bericht über die 46. Jahrestagung des Instituts für Deutsche Sprache in Mannheim, 09.-11. März 2010 (Veronika Kotůlková) "Mittlerin aus Europas Mitte" – 3. MGV-Kongress in Wien, 08.-10. April 2010 (Manfred Glauniger) "Gedichte und Geschichte – Zur poetischen und politischen Rede in Österreich". Tagung der Franz Werfel-Stipendiaten und –Stipendiatinnen in Wien, 16.–17. April 2010 (Roman Kopřiva) Binationales Kolloquium zur Problematik der Migrationsformen im 20. und 21. Jahrhundert in Geschichte und Kunst in Ústí nad Labem, 22.-24. März 2010 und Linz 04.-07. Mai 2010 (Jarmila Jehličková) Ein "hinternationaler" Schriftsteller aus Böhmen: Dritte internationale Johannes-Urzidil-Konferenz in Ústí nad Labem, 05.-08. Mai 2010 (Vera Schneider) "Wir sind Tschechinnen, wir schreiben Deutsch!" – Öffentliche Gesprächsrunde mit deutschsprachigen Autorinnen in Prag, 13. Mai 2010 (Jenifer Johanna Becker) "Überkreuzungen. Verhandlungen kultureller, ethnischer, religiöser und geschlechtlicher Identitäten in österreichischer Literatur und Kultur." MALCA-Tagung in Wien, 22.-25. Mai 2010 (Daniela Drobna, Katharina Haderer, Natalie Lamprecht, Friedrich Teutsch, Esther Wratschko

Ghost anti-crossings caused by interlayer umklapp hybridization of bands in 2D heterostructures

In two-dimensional heterostructures, crystalline atomic layers with differing lattice parameters can stack directly one on another. The resultant close proximity of atomic lattices with differing periodicity can lead to new phenomena. For umklapp processes, this opens the possibility for interlayer umklapp scattering, where interactions are mediated by the transfer of momenta to or from the lattice in the neighbouring layer. Using angle-resolved photoemission spectroscopy to study a graphene on InSe heterostructure, we present evidence that interlayer umklapp processes can cause hybridization between bands from neighbouring layers in regions of the Brillouin zone where bands from only one layer are expected, despite no evidence for Moiré-induced replica bands. This phenomenon manifests itself as ‘ghost’ anti-crossings in the InSe electronic dispersion. Applied to a range of suitable two-dimensional material pairs, this phenomenon of interlayer umklapp hybridization can be used to create strong mixing of their electronic states, giving a new tool for twist-controlled band structure engineering

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701